Home > Companies > Pharmacy Podcast Network

Pharmacy Podcast Network

PharmacyPodcast.com

In March of 2009, Institutional Pharmacy Technology marketing leader, Todd S. Eury, launched the Pharmacy Podcast Show. Over the years, the Pharmacy Podcast has accumulated over 67,000+ listeners and subscribers and is the most popular and downloaded podcast about the Pharmacy Industry. The Pharmacy Podcast Show transformed into the Pharmacy Podcast Network (PPN) in 2016 and will continue to collect the thought leading interviews with some of the most brilliant minds in Pharmacy with over 25 co-hosts. The PPN is a Digital Health Publication and Content Developing partner to the Pharmaceutical industry focusing on Specialty medications, pharmacy business supportive technologies, and industry trends. The PPN is dedicated to Specialty, Retail, Long-term Care, Micro-Chain, – Pharmacy Businesses, Patients, and Pharmacy Students with special content for each of these specific audiences. The PPN is the nation's largest network of podcasts dedicated to the pharmacy professional and industry insiders leading with our 25 co-hosts interviewing dynamic people in the pharmacy industry making a difference for our profession, customers, and patients. The definition of “Innovation” is: A new method, idea, product, or process. Processing, implementing, operating, or designing beyond the status-quo.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

Pharma Tech

BABSON DIAGNOSTICS AND PHARMACY PODCAST NETWORK ANNOUNCE PARTNERSHIP THAT WILL TAKE LISTENERS INSIDE LARGEST RETAIL PHARMACY TRADE SHOW

Babson Diagnostics | July 27, 2022

Babson Diagnostics, a science-first, health care technology company, announced a media partnership with the Pharmacy Podcast Network in connection with the 2022 National Association of Chain Drug Stores’ Total Store Expo, the largest gathering of retailers and suppliers in the health and wellness industry. As part of the partnership, the Pharmacy Podcast Network, the most popular and downloaded podcast about the pharmacy industry, will be integrated into Babson Diagnostics&r...

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Pharma Tech